Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epratuzumab PK/PD in SLE
NCT00113971Phase 2Terminated
- Sponsor
- UCB
- Start
- Apr 2005
- Primary completion
- Mar 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of epratuzumab in systemic lupus erythematosus (SLE), sponsored by UCB. Started Apr 2005; status: terminated.
02
Drugs
epratuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT00113971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113971.